ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 156 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2017. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $2,647,000 | +179.8% | 38,168 | +75.4% | 0.03% | +142.9% |
Q4 2018 | $946,000 | -72.1% | 21,765 | -50.9% | 0.01% | -67.4% |
Q3 2018 | $3,386,000 | -16.6% | 44,350 | -16.1% | 0.04% | -23.2% |
Q2 2018 | $4,061,000 | +28.5% | 52,834 | -14.8% | 0.06% | +14.3% |
Q1 2018 | $3,160,000 | -4.6% | 61,977 | -13.2% | 0.05% | +2.1% |
Q4 2017 | $3,313,000 | -19.9% | 71,440 | -8.0% | 0.05% | -18.6% |
Q3 2017 | $4,138,000 | -13.4% | 77,691 | +1.0% | 0.06% | -19.2% |
Q2 2017 | $4,778,000 | +20.1% | 76,927 | +31.1% | 0.07% | +9.0% |
Q1 2017 | $3,977,000 | +4.3% | 58,670 | +8.2% | 0.07% | -9.5% |
Q4 2016 | $3,813,000 | -28.8% | 54,225 | -28.2% | 0.07% | -21.3% |
Q3 2016 | $5,356,000 | +79.5% | 75,500 | +23.8% | 0.09% | +64.9% |
Q2 2016 | $2,984,000 | +17.9% | 61,000 | +52.5% | 0.06% | +16.3% |
Q1 2016 | $2,532,000 | -43.6% | 40,000 | 0.0% | 0.05% | -38.0% |
Q4 2015 | $4,487,000 | +16.5% | 40,000 | 0.0% | 0.08% | +21.5% |
Q3 2015 | $3,852,000 | – | 40,000 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |